Private equity does not pay a billion-dollar multiple simply because a company describes itself as a “complex generics” player. It pays when scientific complexity has been converted into regulatory approvals, commercial capability and assets that can travel across major global markets.
That is what makes Orbicular Pharmaceutical Technologies worth watching.
Warburg Pincus and CVC Capital Partners have reportedly begun evaluating the Hyderabad-based specialty developer, with Jefferies advising on a potential stake sale. Tata Capital Healthcare Fund may seek a partial or full exit, while early reports place Orbicular’s valuation in the $1 billion to $1.5 billion range. The process remains at an early stage and nothing has yet been signed.
Free Membership Required
You must be a Free member to access this content.
